Daniel S. Char J.D. serves as General Counsel, Secretary of the Company. Mr. Char was the Associate General Counsel - Commercial of Smith & Nephew, a medical technology and biopharmaceutical company, from November 2009 to March 2018. From March 2008 to March 2009, Mr. Char was the General Counsel and Secretary of Targanta Therapeutics, a biopharmaceutical company developing novel antibiotics. Mr. Char received his J.D. from Harvard Law School.
Daniel Char is 59, he's been the General Counsel et Secretary of Evelo Biosciences Inc since 2018. There are 4 older and 9 younger executives at Evelo Biosciences Inc. The oldest executive at Evelo Biosciences Inc is Stephen J. Carriere, 66, who is the VP & Chief Accounting Officer.
Daniel's mailing address filed with the SEC is C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan et Ventures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Evelo Biosciences Inc executives and other stock owners filed with the SEC include: